The Phase 1 portion of the ongoing Phase 1/2 study evaluated one- and two-dose regimens of 5µg of eVLP candidate, VBI-2902a, in 61 healthy adults age 18-54 years After two doses, VBI-2902a induced neutralization titers in 100% of participants, with 4
BERKELEY, Calif.--(BUSINESS WIRE)--Carmot Therapeutics, Inc. (Berkeley, CA), a clinical-stage biotechnology company applying its proprietary therapeutic platform, Chemotype Evolution (CE), to discover and develop disease-modifying therapies in metabolic d
Report underscores salary inequities across race and genders CAMBRIDGE, Mass. & TORONTO--(BUSINESS WIRE)--Bedford Group/TRANSEARCH today announced publication of the 2021 Executive Compensation Report in the biotechnology industry. This is the company’
TORONTO--(BUSINESS WIRE)--NeuPath Health Inc. (TSXV:NPTH) (“NeuPath” or the “Company”), owner and operator of a network of clinics that deliver category-leading treatment for chronic pain, as well as spinal injuries, sports-related injuries, and c
TORONTO--(BUSINESS WIRE)--BioConnect is thrilled to announce a collaboration with HID Global to bring scalable, adaptable authentication to its HID Mobile Access solution alongside a mobile survey option for wellness declaration for employee health status
The TOTUM•63 mode of action clinical study was co-designed by Valbiotis teams, INAF experts and Nestlé Health Science experts, as part of the global strategic partnership with Nestlé Health Science. The study will explore the mode of action of TO
Optimal children’s eye health will require summer outdoor activities, less near work and regular check-ins. TORONTO--(BUSINESS WIRE)--While the horizon of a return to normal seems less distant, a new survey by CooperVision Canada and Maru/Blue1 suggest
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) (“Cybin” or the “Company”), a biotechnology company focused on psychedelic pharmaceutical therapies, is pleased to announce that Adelia Therapeutics Inc. (“Adelia”), a wholly-contro
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) (“Cybin” or the “Company”), a biotechnology company focused on progressing psychedelic therapeutics, today released financial and business highlights for its financial year ended March
Agreement includes commercializing biosimilar candidate of ophthalmology drug ranibizumab (Lucentis®) in Europe, Canada, Israel and global markets TEL AVIV, Israel & ZURICH--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE: and TASE: TEVA) and
FarmersEdge, a global leader in digital agriculture, today announced the appointment of former President of Amazon Canada Fulfillment Services Vibhore Arora as Chief Executive Officer, effective June 6, 2022.
Sign up for one of BAM's newsletter to learn more about bioscience, happenings in Manitoba's bioeconomy, industry conferences, and BAM training events.